Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Ulrich, G. Suna, L. Huber, U. Treder, R. Speich (Zurich, Switzerland). Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension. Eur Respir J 2011; 38: Suppl. 55, 2367

Member's Comments

No comment yet.

Related content which might interest you: Acute pulmonary vasoreactivity to beraprost in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Pulmonary hypertension in COPD Source: Eur Respir J 2008; 32: 1371-1385 Year: 2008 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Medical treatment in persistent pulmonary hypertension after pulmonary thrombendarterectomy in patients with chronic thrombembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 364s Year: 2006 Acute vasodilator response in different forms of pre-capillary pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 The effect of short-acting beta-two-agonist on pulmonary rehabilitation in chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003 The effectiveness of pulmonary rehabilitation in Russian patients with COPD complicated by pulmonary artery hypertension Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009 Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009